Fat Cell Size and Adipokine Expression in Relation to Gender, Depot, and Metabolic Risk Factors in Morbidly Obese Adolescents

Naomi Berrie Diabetes Center, Columbia University, College of Physicians and Surgeons, New York, United States.
Obesity (Impact Factor: 4.39). 03/2014; 22(3). DOI: 10.1002/oby.20528
Source: PubMed

ABSTRACT Objective: To understand the regulation of adipocyte size and adipokine expression in relation to gender, anatomic location, adiposity, and metabolic risk factors in adolescents with morbid obesity. Design and Methods: Adipocyte size and adipokine expression in paired abdominal subcutaneous (SAT) and omental (VAT) surgical adipose tissues were related to gender, anatomic location, adiposity, and metabolic risk factors in a group of morbidly obese adolescents. Results: Significant depot- and/or gender-related differences in adipocyte size and adipokine expression were detected. Adjusted for BMI, adipocyte size in both depots was larger in males than in females and was a major predictor of mRNA levels of leptin, PAI-1, and adiponectin. Gender, but not adipocyte size, was significantly correlated with pro-inflammatory cytokine expression. BMI and waist circumference were correlated positively with VAT adipocyte size and negatively with SAT adipocyte size. VAT adiponectin and IL-6 expression levels were major predictors of HDL cholesterol concentrations, independent of gender, adiposity, and insulin sensitivity. Conclusions: Adipose tissue morphology and function in obese adolescents are influenced by gender and anatomic location; the pattern of gender- and depot-related differences in adipocyte size and adipokine expression suggests that adolescent males, relative to the females, are at increased risk for obesity-related metabolic co-morbidities.

  • 12/2014; 3(4):242-255. DOI:10.4161/adip.28546
  • [Show abstract] [Hide abstract]
    ABSTRACT: The increasing prevalence of diabetes and its complications heralds an alarming situation worldwide. Obesity-associated changes in circulating adiponectin concentrations have the capacity to predict insulin sensitivity and are a link between obesity and a number of vascular diseases. One obvious consequence of obesity is a decrease in circulating levels of adiponectin, which are associated with cardiovascular disorders and associated vascular comorbidities. Human and animal studies have demonstrated decreased adiponectin to be an independent risk factor for cardiovascular disease. However, in animal studies, increased circulating adiponectin alleviates obesity-induced endothelial dysfunction and hypertension, and also prevents atherosclerosis, myocardial infarction, and diabetic cardiac tissue disorders. Further, metabolism of a number of foods and medications are affected by induction of adiponectin. Adiponectin has beneficial effects on cardiovascular cells via its antidiabetic, anti-inflammatory, antioxidant, antiapoptotic, antiatherogenic, vasodilatory, and antithrombotic activity, and consequently has a favorable effect on cardiac and vascular health. Understanding the molecular mechanisms underlying the regulation of adiponectin secretion and signaling is critical for designing new therapeutic strategies. This review summarizes the recent evidence for the physiological role and clinical significance of adiponectin in vascular health, identification of the receptor and post-receptor signaling events related to the protective effects of the adiponectin system on vascular compartments, and its potential use as a target for therapeutic intervention in vascular disease.
    Vascular Health and Risk Management 01/2015; 11:55. DOI:10.2147/VHRM.S48753
  • [Show abstract] [Hide abstract]
    ABSTRACT: Accumulation of fat mass in obesity may result from hypertrophy and/or hyperplasia and is frequently associated with adipose tissue (AT) dysfunction in adults. Here, we assessed early alterations in AT biology and function by comprehensive experimental and clinical characterization of 171 AT samples from lean and obese children aged 0 to 18 years.We show an increase in adipocyte size and number in obese compared to lean children beginning in early childhood. These alterations in AT composition in obese children were accompanied by decreased basal lipolytic activity and significantly enhanced stromal vascular cell proliferation in vitro, potentially underlying the hypertrophy and hyperplasia seen in obese children, respectively. Furthermore, macrophage infiltration, including the formation of crown-like structures, was increased in AT of obese children from 6 years on, and was associated with higher hsCRP serum levels. Clinically, adipocyte hypertrophy was not only associated with leptin serum levels, but was highly and independently correlated with HOMA-IR as a marker of insulin resistance in children.In summary, we show that adipocyte hypertrophy is linked to increased inflammation in AT in obese children thereby providing evidence that obesity-associated AT dysfunction develops in early childhood and is related to insulin resistance.
    Diabetes 11/2014; DOI:10.2337/db14-0744 · 8.47 Impact Factor

Full-text (3 Sources)

Available from
Oct 8, 2014